Loading insider details...
Beta
Latest Form 4 (Jun 23, 2026): Exercise/Conversion of 29,600 AVIR shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 23, 2026 | Atea Pharmaceuticals, Inc. (AVIR) | Exercise/Conversion | 29,600 | n/a |
| May 7, 2026 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/Award | 3,796 | n/a |
| Mar 2, 2026 | Ovid Therapeutics Inc. (OVID) | Grant/Award | 65,000 | n/a |
| Jun 24, 2025 | Atea Pharmaceuticals, Inc. (AVIR) | Exercise/Conversion | 29,600 | n/a |
| Jun 18, 2025 | Ovid Therapeutics Inc. (OVID) | Grant/Award | 45,000 | n/a |
| May 2, 2025 | HALOZYME THERAPEUTICS, INC. (HALO) | Grant/Award | 4,165 | n/a |
| Dec 16, 2024 | Ovid Therapeutics Inc. (OVID) | Grant/Award | 90,000 | n/a |
| Jun 21, 2024 | Atea Pharmaceuticals, Inc. (AVIR) | Grant/Award | 29,600 | n/a |
| Jun 18, 2024 | Atea Pharmaceuticals, Inc. (AVIR) | Exercise/Conversion | 33,150 | n/a |
| Jun 4, 2024 | Fusion Pharmaceuticals Inc. (FUSN) | Disposition to Issuer | 30,000 | n/a |